Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols.

Aerosol particle size influences airway drug deposition. Current inhaler devices are inefficient, delivering a heterodisperse distribution of drug particle sizes where, at best, 20% reaches the lungs. Monodisperse aerosols are the appropriate research tools to investigate basic aerosol science concepts within the human airways. We hypothesized that engineering such aerosols of albuterol would identify the ideal bronchodilator particle size, thereby optimizing inhaled therapeutic drug delivery. Eighteen stable mildly to moderately asthmatic patients [mean forced expiratory volume in 1 s (FEV1) 74.3% of predicted] participated in a randomized, double-blind, crossover study design. A spinning-top aerosol generator was used to produce monodisperse albuterol aerosols that were 1.5, 3, and 6 microm in size, and also a placebo, which were inhaled at cumulative doses of 10, 20, 40, and 100 microg. Lung function changes and tolerability effects were determined. The larger particles, 6 and 3 microm, were significantly more potent bronchodilators than the 1.5-microm and placebo aerosols for FEV1 and for the forced expiratory flow between exhalation of 25 and 75% of forced vital capacity. A 20-microg dose of the 6- and 3-microm aerosols produced FEV1 bronchodilation comparable to that produced by 200 microg from a metered-dose inhaler. No adverse effects were observed in heart rate and plasma potassium. The data suggest that in mildly to moderately asthmatic patients there is more than one optimal beta2-agonist bronchodilator particle size and that these are larger particles in the higher part of the respirable range. Aerosols delivered in monodisperse form can enable large reductions of the inhaled dose without loss of clinical efficacy.

[1]  B. Jonson,et al.  Effect of inhaled terbutaline sulphate in relation to its deposition in the lungs. , 1992, Pulmonary pharmacology.

[2]  M. Svartengren,et al.  Lung deposition and extremely slow inhalations of particles. Limited effect of induced airway obstruction. , 1999, Experimental lung research.

[3]  W. H. Walton.  The Mechanics of Aerosols , 1966 .

[4]  I. Pavord,et al.  Systemic effects of salbutamol and salmeterol in patients with asthma. , 1994, Thorax.

[5]  D. Pavia,et al.  Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. , 1982, European journal of respiratory diseases. Supplement.

[6]  H. Chrystyn,et al.  Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. , 1993, Thorax.

[7]  S. Spiro,et al.  Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. , 1993, Thorax.

[8]  S. Goodall,et al.  Aerosolization of protein solutions using thermal inkjet technology. , 2002, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[9]  The optimal particle size for beta-adrenergic aerosols in mild asthmatics * , .

[10]  Pieter Zanen,et al.  The optimal particle size for β-adrenergic aerosols in mild asthmatics , 1994 .

[11]  O. Usmani,et al.  A system for the production and delivery of monodisperse salbutamol aerosols to the lungs. , 2003, International journal of pharmaceutics.

[12]  Morrow Pe.  Conference on the scientific basis of respiratory therapy. Aerosol therapy. Aerosol characterization and deposition. , 1974 .

[13]  M. Tanemura,et al.  Hyperreactive site in the airway tree of asthmatic patients revealed by thickening of bronchial muscles. A morphometric study. , 1990, The American review of respiratory disease.

[14]  T. Martonen,et al.  The influence of hygroscopic growth upon the deposition of bronchodilator aerosols in upper human airways , 1983 .

[15]  R. V. Lourenço,et al.  Calculated deposition of inhaled particles in the airway generations of normal subjects. , 1979, Journal of applied physiology: respiratory, environmental and exercise physiology.

[16]  Clarke Sw.  Aerosols as a way of treating patients. , 1986 .

[17]  P. Barnes,et al.  Localization of beta-adrenoreceptors in mammalian lung by light microscopic autoradiography. , 1982, Nature.

[18]  E. Weibel.  Morphometry of the Human Lung , 1965, Springer Berlin Heidelberg.

[19]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[20]  D. Mitchell,et al.  Effect of particle size of bronchodilator aerosols on lung distribution and pulmonary function in patients with chronic asthma. , 1987, Thorax.

[21]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.

[22]  S J Farr,et al.  Aerosol deposition in the human lung following administration from a microprocessor controlled pressurised metered dose inhaler. , 1995, Thorax.

[23]  J. Heyder,et al.  Measurement of the hygroscopicity of pharmaceutical aerosols in situ , 1995 .

[24]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[25]  H. Saltzman,et al.  Conference on the scientific basis of respiratory therapy. , 1974, The American review of respiratory disease.

[26]  J. Lammers,et al.  The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler , 1998, European Journal of Clinical Pharmacology.

[27]  M. Newhouse,et al.  Site of beta-adrenergic receptors in the respiratory tract: use of fenoterol administered by two methods. , 1978, Chest.

[28]  J N Pritchard,et al.  The influence of lung deposition on clinical response. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[29]  B. Lipworth,et al.  Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. , 1995, Thorax.

[30]  S. Clarke,et al.  Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition. , 1989, Chest.

[31]  H. Wagner,et al.  The effect of bronchial obstruction on central airway deposition of a saline aerosol in patients with asthma. , 1986, The American review of respiratory disease.

[32]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[33]  A. Wilson,et al.  Dose-response effects of two sizes of monodisperse isoproterenol in mild asthma. , 1990, The American review of respiratory disease.

[34]  T. Clark,et al.  The importance of particle size in response to inhaled bronchodilators. , 1982, European journal of respiratory diseases. Supplement.

[35]  J. Heyder,et al.  Deposition of particles in the human respiratory tract in the size range 0.005–15 μm , 1986 .

[36]  B. Laube,et al.  Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. , 2000, Chest.

[37]  P. Morrow.  Conference on the scientific basis of respiratory therapy. Aerosol therapy. Aerosol characterization and deposition. , 1974, The American review of respiratory disease.

[38]  P. Morrow.  Aerosol characterization and deposition , 1974 .

[39]  M. Newhouse,et al.  Aerosol penetration into the lung; influence on airway responses. , 1981, Chest.

[40]  A. Wanner.  Clinical perspectives: role of the airway circulation in drug therapy. , 1996, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[41]  D. Pavia,et al.  Effect of aerosol particle size on bronchodilatation with nebulised terbutaline in asthmatic subjects. , 1986, Thorax.